Eli Lilly and Company (LLY) Earns Fresh Bullish Calls from Analysts

Eli Lilly and Company (NYSE:LLY) is among the most profitable healthcare stocks to buy. On January 26, Srikripa Devarakonda, an analyst at Truist Financial, maintained a Buy rating on Eli Lilly and Company (NYSE:LLY), while setting a price target of $1,182. This reflects an upside potential of 11%.

Earlier, on January 20, Bernstein maintained an Outperform rating and a price target of $1,300 on Eli Lilly and Company (NYSE:LLY), citing the company’s efforts to capitalize on the oral medication opportunity. What’s even more interesting is that the healthcare giant also remains focused on global expansion and diabetes growth, which is anticipated to materialize next year.

According to Bernstein, Eli Lilly and Company’s (NYSE:LLY) beyond-incretin pipeline will need to increasingly demonstrate its next leg of growth by the end of the decade. The firm is positive about the company’s foundations, whilst believing 2026 to be the year for potential upside surprises. Having said that, the firm recognised the company as its top stock pick in the sector.

​Eli Lilly and Company (NYSE:LLY) is an Indiana-based company that discovers, develops, and markets human pharmaceuticals. Founded in 1876, the company is committed to improving people’s lives worldwide.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.